Preparation method and application of inhalation vaccine based on polydopamine surface modification

Through nano-formulation based on polydopamine surface modification, the problem of inhaled vaccines in the penetration of mucosal barriers and low uptake of dendritic cells is solved, and the efficient enrichment and rapid immune response of lung vaccines are achieved, which simplifies preparation The process has good industrialization prospects.

CN118949053APending Publication Date: 2024-11-15NANJING TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410988440.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing inhaled vaccines are inefficient in crossing the lung mucosal barrier and dendritic cell uptake, making it difficult to achieve effective lung vaccine enrichment and rapid immune response.

Method used

Using nanoformulations based on polydopamine surface modification, prepared by polymerizing albumin-encapsulated layered dihydroxide with dopamine and glutaraldehyde, enhancing the mucosal penetration and dendritic cell targeting capabilities of the nanoformulations, and nucleic acids are used. Immune-like adjuvants bind to protein antigens to form an inhaled vaccine for nasal administration.

Benefits of technology

It significantly improves the enrichment of vaccines in the lungs, activation of dendritic cells and antigen presentation effects, achieves rapid intra-proximal lymph node antigen presentation, simplifies the preparation process, and has the prospect of industrial implementation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949053A_ABST
    Figure CN118949053A_ABST
Patent Text Reader

Abstract

The invention relates to the field of vaccine preparation methods, in particular to a preparation method and application of an inhalation vaccine based on polydopamine surface modification, and the preparation method comprises the following steps: (1) uniformly mixing a bovine serum albumin solution and a layered double hydroxide aqueous solution to prepare a bovine serum albumin coated layered double hydroxide solution; and (2) enabling the bovine serum albumin to wrap the layered double hydroxide solution, dopamine and glutaraldehyde to react to prepare the nano preparation based on polydopamine surface modification. The nano preparation provided by the invention can improve the ingestion of vaccines by dendritic cells and realize rapid presentation of antigens in near-end lymph nodes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the preparation and application fields of nanometer medicines, and in particular to a preparation method and application of an inhalation vaccine based on surface modification of polydopamine. Background Art

[0002] This section merely provides background information related to the present disclosure and is not necessarily prior art.

[0003] Respiratory diseases are a major problem affecting the health of Chinese residents. The development of vaccines has provided support for the prevention and treatment of a variety of respiratory diseases, especially for respiratory viral infections and lung cancer. In view of the characteristics of respiratory diseases, inhaled vaccines have natural advantages over traditional intravenous or intramuscular vaccines and are a very promising vaccination method. The advantages of inhaled vaccines are mainly reflected in: (1) the ability to specifically improve the enrichment of vaccine preparations in the lungs, (2) rapid initiation of local immune responses, and (3) simulating the path of pathogen invasion for vaccination. However, during the application of inhaled vaccines, it is necessary for the vaccine antigen to pass through the lung mucosal barrier after inhalation and be effectively taken up by dendritic cells (DCs). In addition, the targeted addition of immune adjuvants can improve the immune response effect caused by vaccines, such as the common DNA adjuvant CpG and RNA adjuvant 3pRNA. To this end, the present invention provides a method for preparing a nanoformulation based on polydopamine surface modification that can improve lung mucosal penetration and DC uptake, and the application of inhaled vaccines using such nanoformulations to integrate protein vaccine antigens and RNA adjuvants. Summary of the invention

[0004] Purpose of the invention: The technical problem to be solved by the present invention is to provide a nanoformulation based on the surface modification of polydopamine and a preparation method thereof, and an inhalable vaccine based on the nanoformulation based on the surface modification of polydopamine and a preparation method thereof in view of the deficiencies in the prior art.

[0005] In order to solve the above technical problems, the present invention discloses the following technical solutions:

[0006] In a first aspect, the present invention discloses a nanoformulation based on surface modification of polydopamine and a preparation method thereof.

[0007] The preparation method of the nano preparation based on polydopamine surface modification is to prepare the nano preparation by polymerization reaction of a solution of albumin-wrapped layered double hydroxide, dopamine and an aldehyde compound.

[0008] Specifically, the preparation method comprises the following steps:

[0009] (1) uniformly mixing layered double hydroxide (LDH) nanoparticles and a bovine serum albumin (BSA) solution to prepare a solution for preparing BSA-coated LDH nanoparticles;

[0010] (2) A solution of bovine serum albumin-coated layered double hydroxide, dopamine and glutaraldehyde were reacted to prepare a nanoformulation based on polydopamine surface modification.

[0011] In step (1), the LDH nanoparticles are LDH nanomaterials containing Mg and Al bimetallic elements and synthesized by a hydrothermal method, and the general molecular formula thereof is Mg n Al(OH) 2(n+1) Cl (1-x) (CO3) x .mH2O; wherein n is in the range of 2-4, x is in the range of 0-1, and m is an arbitrary number; preferably, n is in the range of 2.8-3.2, and x is in the range of 0-0.2.

[0012] In step (1), the mass ratio of BSA to LDH is 1-8:1, preferably 1-6:1, preferably 4.5:1; the concentration of the LDH solution is calculated by weighing after oven drying; the concentration of the bovine serum albumin solution is 3.5-5.5 mg / mL, and the concentration of the layered double hydroxide aqueous solution is 0.5-1.5 mg / mL; the mass ratio of the layered double hydroxide to the albumin solution is 1:1-8, preferably 1:3.5-5.5.

[0013] In step (1), the uniform mixing method is magnetic stirring for 25-35 minutes, such as 30 minutes (total volume ≥ 100 μL) or vortex oscillation for 25-35 seconds, such as 30 seconds (volume < 100 μL).

[0014] In step (2), a solution of layered double hydroxide coated with bovine serum albumin is mixed with a dopamine solution, and then reacted with a glutaraldehyde solution to prepare a nano-preparation based on surface modification of polydopamine.

[0015] Wherein, the mass ratio of the bovine serum albumin-coated layered double hydroxide to dopamine is 2:0.25-2, preferably 2:0.75-1.25; the concentration of the dopamine solution is 0.25-2 mg / mL, preferably 0.5-1.5 mg / mL; the concentration of the BSA-coated LDH solution is 1.5-2.5 mg / mL, preferably 2 mg / mL.

[0016] Wherein, when the total volume of the solution of the layered double hydroxide coated with bovine serum albumin and the dopamine solution is ≥100 μL, the mixing is stirring for 25-35 minutes, such as 30 minutes; when the total volume of the solution of the layered double hydroxide coated with bovine serum albumin and the dopamine solution is <100 μL, the mixing is stirring and vortexing for 25-35 seconds, such as 30 seconds.

[0017] The volume ratio of the bovine serum albumin-coated layered double hydroxide solution to the 2%-6% mass concentration glutaraldehyde aqueous solution is 1 mL:5-20 μL, preferably 1 mL:20 μL; the concentration of the glutaraldehyde solution is 4%; preferably, the reaction time is 25-35 min.

[0018] In a second aspect, the present invention discloses an inhalable vaccine prepared based on the polydopamine surface-modified nanoformulation described in the first aspect.

[0019] Wherein, the inhalation vaccine is composed of the nano preparation loaded with nucleic acid immune adjuvant and protein antigen.

[0020] The preparation method of the inhalation vaccine is to add nucleic acid immune adjuvant and protein antigen into the nano preparation, mix them, and obtain the inhalation vaccine.

[0021] Specifically, the preparation method of the inhalable vaccine includes mixing protein antigens, bovine serum albumin solution and layered double hydroxide aqueous solution to prepare bovine serum albumin-coated layered double hydroxide, then polymerizing with dopamine and glutaraldehyde to prepare a nano preparation based on polydopamine surface modification, and mixing the obtained nano preparation with a nucleic acid immune adjuvant to obtain an inhalable vaccine.

[0022] Wherein, the dosage of the nucleic acid immune adjuvant is: for every 1 μg of nucleic acid immune adjuvant, the corresponding mass of LDH is 20-80 μg, preferably 30-60 μg, preferably 40 μg.

[0023] Wherein, the dosage of the protein antigen is: the mass ratio of LDH / protein antigen is 1:0.2-1, such as 1:0.2-0.5, 1:1-0.25, 1:0.25.

[0024] Wherein, when the total volume of nucleic acid immune adjuvant, protein antigen and nano preparation is ≥100 μL, the mixing is stirring for 25-35 min; when the total volume of nucleic acid immune adjuvant, protein antigen and nano preparation is <100 μL, the mixing is stirring vortex oscillation for 25-35 s.

[0025] In the present invention, the dosage form of the inhalation vaccine is a nasal administration dosage form.

[0026] In the present invention, after the mice are intramuscularly injected with anesthesia, 30-50 μL of the inhalation vaccine solution is dripped into the nasal cavity, preferably, 40 μL is dripped into the nasal cavity.

[0027] In the present invention, the inhalation vaccine is a respiratory disease vaccine, such as a lung disease vaccine, such as an influenza disease vaccine, etc.

[0028] The nanoformulation described in the present invention uses layered double hydroxide (LDH) as a template and is modified with surface polydopamine to enhance the ability of mucosal penetration and dendritic cell targeting. The nanoformulation can be loaded with nucleic acid immune adjuvants and protein antigens. After nasal inhalation, it can significantly improve the activation of lung dendritic cells and antigen presentation effect, and is expected to be used in the development of inhaled vaccines for lung diseases.

[0029] Beneficial effects:

[0030] (1) The nanoformulation of the present invention can effectively penetrate the lung mucosal barrier and improve the accumulation of the vaccine in the lungs through inhalation vaccination.

[0031] (2) The nanoformulation of the present invention can enhance the uptake of vaccines by dendritic cells and achieve rapid antigen presentation in proximal lymph nodes.

[0032] (3) The preparation method of the present invention is simple, the reaction conditions are mild, and it is easy to operate. It optimizes the surface modification process of nanomaterials based on layered double hydroxides and has the prospect of industrial implementation. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.

[0034] Figure 1 It is a process flow chart of the inhalation vaccine of the present invention.

[0035] Figure 2 Optimization of conditions for albumin coating of layered double hydroxides.

[0036] Figure 3 Optimization of modification conditions for in situ polymerization of dopamine.

[0037] Figure 4 These are transmission electron microscopy observation photos of nanoformulations and intermediates in their synthesis process and statistical results of particle size distribution.

[0038] Figure 5 These are the results of an in vitro mucosal penetration experiment.

[0039] Figure 6 Results of in vitro dendritic cell phagocytosis of nanoformulations.

[0040] Figure 7 To evaluate the efficacy of inhaled vaccines on dendritic cell maturation and antigen presentation in vitro.

[0041] Figure 8 This is the distribution of relevant fluorescence in the main organs in the chest cavity of mice after nasal injection of inhaled vaccine. DETAILED DESCRIPTION

[0042] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0043] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0044] Example 1

[0045] This embodiment is to prepare a polydopamine-modified nanoformulation. The technical process of the nanoformulation and the subsequent inhalation vaccine prepared on this basis is as shown in the attached Figure 1 shown.

[0046] 1. The method for preparing a large amount of nanoparticles under sterile conditions is as follows:

[0047] Step 1: Prepare 1 mL of a sterile 1 mg / mL layered double hydroxide (LDH) aqueous solution, where the theoretical chemical formula of LDH is Mg3Al(OH)8Cl.2H2O; prepare 1 mL of a sterile 4.5 mg / mL bovine serum albumin aqueous solution, and add the bovine serum albumin solution dropwise to the sterile EP tube of the LDH solution using a pipette in the sterile environment of a biosafety cabinet and under magnetic stirring, and continue stirring for 30 minutes to allow the coating to be complete. The resulting solution is the albumin-coated LDH solution (LB).

[0048] Step 2: Prepare 1 mL of the above LB solution with a concentration of 2 mg / mL, and prepare 1 mL of a freshly prepared 1 mg / mL dopamine aqueous solution. In the sterile environment of the biosafety cabinet and under magnetic stirring conditions, add the dopamine solution dropwise to the LB solution, and continue stirring for 5 minutes to disperse evenly. Then drop 20 μL of a 4% glutaraldehyde solution into it, and continue stirring for 30 minutes to fully react to obtain a polydopamine-modified nanoformulation PDLB suspension. The mass concentration of PDLB measured by freeze-drying is 1.1-1.2 mg / mL.

[0049] 2. The method for rapidly preparing a small amount of nanoparticles under sterile conditions is as follows:

[0050] Step 1: Prepare 40 μL of a sterile 1 mg / mL layered double hydroxide (LDH) aqueous solution, where the theoretical chemical formula of LDH is Mg3Al(OH)8Cl.2H2O; prepare 40 μL of a 4.5 mg / mL sterile bovine serum albumin aqueous solution, and in the sterile environment of a biosafety cabinet and under magnetic stirring, quickly add the bovine serum albumin solution to a sterile EP tube containing the LDH solution using a pipette, and vortex for 30 seconds to obtain an albumin-coated LDH solution (LB).

[0051] Step 2: Prepare 40 μL of the above LB solution with a concentration of 2 mg / mL, and prepare 40 μL of a freshly prepared 1 mg / mL dopamine aqueous solution. In the sterile environment of the biosafety cabinet and under magnetic stirring, add the dopamine solution dropwise to the LB solution and vortex for 30 seconds. Then drop 20 μL of a 0.16% glutaraldehyde solution into it, vortex for 30 seconds, and obtain a polydopamine-modified nanoformulation PDLB suspension. The mass concentration of PDLB obtained by freeze drying is 1.0-1.2 mg / mL.

[0052] The total concentration of the PDLB suspension obtained by the two methods was calculated by freeze drying and weighing. The concentration of the solution obtained by the two preparation methods was 1.0-1.2 mg / mL. The concentration of LDH in the PDLB suspension obtained by the two methods was determined by ICP. After multiple measurements, the concentration of LDH was about 0.16 mg / mL under the condition of 1.2 mg / mL PDLB solution concentration. The subsequent dynamic light scattering characterization confirmed that the particle size difference of the nanoformulations obtained by the two preparation methods was within 10%.

[0053] Example 2

[0054] This example is a method for further preparing an inhalation vaccine based on the nanoformulation prepared by any method in Example 1. The specific method is as follows:

[0055] Inhalation vaccine PDLB / R containing only nucleic acid adjuvant: The nanoformulation PDLB was prepared according to the method shown in Example 1, 100 μL of PDLB (wherein the LDH concentration was 0.16 mg / mL) and an equal volume of 3p-shRNA (concentration was 4 μg / mL) were mixed, and vortexed for 30 seconds to obtain the inhalation vaccine PDLB / R containing nucleic acid adjuvant.

[0056] Inhalation vaccine PDLB@OVA containing only antigen: Prepare an albumin aqueous solution containing OVA antigen protein, wherein the concentrations of OVA antigen protein and albumin are 0.5 mg / mL and 4.5 mg / mL, respectively. According to the method shown in Example 1, the albumin solution containing OVA antigen protein is added to the LDH solution instead of the albumin solution in Example 1, and the inhalation vaccine PDLB@OVA containing OVA antigen is prepared.

[0057] Inhalation vaccine PDLB / R@OVA containing antigen and nucleic acid adjuvant: Prepare an albumin solution containing OVA antigen protein, wherein the concentrations of antigen protein and albumin are 0.5 mg / mL and 4.5 mg / mL, respectively. According to the method shown in Example 1, the albumin solution containing antigen protein is added to the LDH solution instead of the albumin solution in Example 1. Then, 100 μL of PDLB (wherein the LDH concentration is 0.16 mg / mL) and an equal volume of 3p-shRNA (concentration is 4 μg / mL) are mixed and vortexed for 30 seconds to obtain the inhalation vaccine PDLB / R@OVA containing antigen and nucleic acid adjuvant.

[0058] The sequence of 3p-shRNA is 5'-pppGGAGCAAAAGCAGGGUGACAAAGACAUAA UGGAUCCAAACACUGUGUCAAGCUUUCAGGUAGAUUGCUUUCUUUGGCAUGU CCGCAAAC-3' (SEQ ID NO. 1). This type of nucleic acid adjuvant can be used to prevent influenza diseases such as H1N1 in mice.

[0059] Example 3

[0060] This example characterizes the nanoformulation prepared by method 1 in Example 1. During the condition optimization process, the parameters used that are different from those of the first method in Example 1 have been specifically explained.

[0061] The present invention uses dynamic light scattering, surface potential measurement and transmission electron microscopy (TEM) observation to characterize the obtained nanoformulation. The details are as follows:

[0062] The particle size, polymer dispersion coefficient and surface potential under different LDH and albumin BSA mass ratios were characterized by dynamic light scattering and surface potential measurement. The parameters different from Example 1 were: the mass ratio of LDH and albumin BSA was adjusted to 1:2, 1:2.5, 1:5 and 1:6. Figure 2As shown in the figure, the particle size of LB reaches a smaller size (about 200nm) after the LDH:BSA ratio is higher than 1:2.5, and the polymer dispersion coefficient reaches a lower value (about 0.35). The change of LDH:BSA ratio has no significant change on the surface potential of LB, and the surface potential under the tested conditions is about -18mV. Similarly, after multiple comparisons, the LDH:BSA mass ratio of 1:4.5 was finally selected as the optimized condition. Under this condition, the LB particle size obtained is about 200nm, and the repeatability is good.

[0063] Dynamic light scattering and surface potential measurement were used to characterize the various parameters of the nanoformulation PDLB under different dopamine and glutaraldehyde input conditions. The parameters different from Example 1 are: (i) the mass concentration of the dopamine aqueous solution was selected to be 0.25, 0.5, 0.75, 1, 1.5 and 2 mg / mL respectively; (ii) the volume of glutaraldehyde was 5, 10, 20 μL. And LDH (1 mg / mL) and LB (1 mg / mL) aqueous solutions were selected as control groups. The mass concentration of the dopamine aqueous solution was optimized according to condition (i): as shown in the attached figure. Figure 3 As shown, with the increase of dopamine, the particle size of the PDLB nanoformulation remains between 200-300nm, and the surface potential gradually increases from about -18mV to about -13mV with the addition of dopamine. Through multiple comparisons, the dopamine solution concentration of 0.75-1mg / mL was finally selected. At this time, the PDLB particle size obtained was between 200-240nm and the surface potential was about -15mV. The volume of 4% glutaraldehyde was optimized according to condition (ii): Under the conditions of the selected LDH:BSA mass ratio of 1:4.5 and the dopamine solution concentration of 1mg / mL, changing the glutaraldehyde volume had little effect on the size of PDLB. In order to reduce the error caused by the small volume, 20μL was finally selected as the optimized condition. The PDLB particle size obtained under the optimized conditions was about 200-240nm, the surface potential was about -15mV, and the repeatability was good.

[0064] The transmission electron micrograph of the nanoparticle PDLB prepared by the present invention (method 1 of embodiment 1) is shown in the attached figure. Figure 4 As shown. The prepared surface polydopamine-modified PDLB basically retains the hexagonal structure of the initial LDH, and at the same time exhibits a certain degree of lace-like shape, indicating that the surface of the material has been successfully modified with polydopamine. Statistics of the size of the material in the transmission electron microscopy photos show that the size of PDLB is about 75nm on average, which is slightly larger than the statistical average size of LDH (70nm), indicating the existence of PDLB outer layer modification.

[0065] Example 4

[0066] This example is an in vitro evaluation method for the ability of the nanoformulation prepared by Method 1 in Example 1 to cross the mucus layer.

[0067] Prepare an agarose solution with a concentration of 3 mg / L, heat it in a microwave oven to melt and fully dissolve, then add it to a 24-well plate at 1 mL / well and let it stand at room temperature until it forms a gel. Then add 0.5 mL of a 5 mg / mL mucin aqueous solution to each well. Prepare LDH, LB, and PDLB nanoformulation aqueous solutions with a total particle concentration of 5 mg / mL, add 0.5 mL to the well plate respectively, and incubate at room temperature for a certain period of time. Then aspirate the upper layer of liquid and wash the gel 3 times with deionized water. After the gel is taken out and heated to melt, the content of aluminum ions in the solution is quantitatively detected using the chrome azuro blue S spectrophotometry method shown in GB / T 5750.6-2006, and the permeability of the nanoparticles is calculated according to the following formula.

[0068] Nanoparticle permeability (%) = (Al concentration in gel × total nanosuspension volume ÷ Al mass fraction) / total nanoparticle amount × 100%.

[0069] As attached Figure 5 As shown, the mucus penetration rate of PDLB nanoformulation is higher than that of LDH and LB, and can reach about 25% within 72 hours. This result indicates that PDLB nanoformulation has a higher ability to penetrate mucus.

[0070] Example 5

[0071] This example is an in vitro evaluation of the dendritic cell affinity of the nanoformulation prepared by method 2 in Example 1.

[0072] LB and PDLB were prepared using FITC-labeled LDH to track the phagocytosis of particles by cells. FITC-labeled LDH was used as the control group. DC2.4 cells were cultured at 5×10 4 The cells were inoculated at a density of 10 cells / well in a 24-well plate, and each well contained 0.5 mL of DMEM medium. The material was diluted with the medium to a final concentration of 40 μg / mL of LDH in the material, and cultured for 4 hours in the dark. After the administration, each well was rinsed twice with pre-cooled PBS buffer. The cells were collected by centrifugation after trypsin digestion, and the centrifugation condition was 1500 rpm for 5 minutes. The obtained cells were resuspended in 100 μL of pre-cooled PBS, and the FITC positivity of each group of cells was determined by flow cytometry, and the average fluorescence intensity was calculated.

[0073] As attached Figure 6 As shown, after 4 hours of incubation, the PDLB nanoformulation can be effectively phagocytosed by DC2.4 cells, and the obtained FITC-positive cells are about 95%. This result shows that the PDLB nanoformulation has good affinity for dendritic cells.

[0074] Example 6

[0075] This example is an evaluation of the immune effect of the inhaled vaccine prepared in Example 2 on priming dendritic cells, including two parts: an evaluation of the induction of maturation of dendritic cells and an evaluation of specific antigen cross-presentation.

[0076] Methods for evaluating inhaled vaccines for induction of dendritic cell maturation are as follows:

[0077] DC2.4 cells were collected at 5×10 4 The density of cells / well was inoculated in a 24-well plate, and the prepared different vaccines were added one day after plating. The condition was that each well contained 0.5mL of DMEM medium, and the content of LDH in the nanovaccine was 20μg / mL. After 24h incubation, each well was rinsed twice with pre-cooled PBS buffer, and the cells were collected by trypsin digestion. The cells were collected by centrifugation into EP tubes, and 100μL of antibody cocktail was added to each tube for light-proof staining. The antibody cocktail for staining contained anti-mouse CD86-PE, anti-mouse CD80-PerCP-Cy5.5 and anti-mouse CD40-APC, and all antibodies were diluted 1:1000 in PBS containing 2% FBS. After incubation for 20min under light-proof conditions, the cells were resuspended in 200μL cold PBS after centrifugation again and stored on ice. The cells in each group were detected by flow cytometry, and the average fluorescence intensity of cell surface markers was analyzed using Flowjo software.

[0078] Methods for assessing specific antigen cross-presentation are as follows:

[0079] DC2.4 cells were collected at 5×10 4 The cells were inoculated at a density of 10 cells / well in a 24-well plate. One day after plating, the inhalation vaccine was added. The condition was that each well contained 0.5 mL of culture medium, and the LDH content in the inhalation vaccine was 20 μg / mL. After incubation for 24 hours, the cells were harvested and stained with antibodies (anti-mouse CD80-PerCP-Cy5.5 and anti-mouse H-2K b -PE staining), and flow cytometry was used to measure the expression of CD80 and H-2K b The percentage of double-negative, single-positive and double-positive cells on the cell surface after antibody labeling was used to analyze the phenotype of DC cells after OVA antigen presentation.

[0080] As attached Figure 7As shown in the figure, compared with cells without drug addition (Control), nanoformulation PDLB and PDLB loaded with 3p-shRNA (PDLB / R) can induce DC2.4 surface maturation-related markers CD86, CD80 and CD40 to different degrees, indicating that PDLB and PDLB / R have the ability to induce DC maturation. At the same time, the inhaled vaccines containing OVA antigen PDLB@OVA and PDLB / R@OVA can simultaneously induce the expression of H-2K bound by CD80 and SIINFEKL on the surface of DC2.4. b The up-regulation of expression indicates that the prepared inhaled vaccine has a significant ability to enhance the cross-presentation of dendritic cell antigens, which is essential for the initiation of subsequent anti-OVA-related immune processes.

[0081] Example 7

[0082] This example is an evaluation of the inhaled vaccine prepared in Example 2 in vivo distribution.

[0083] LDH, LB, and PDLB nanoparticles labeled with RITC were used to track the distribution of the vaccine in the thoracic cavity after the vaccine was inhaled through the nasal cavity of mice. Female C57BL / 6 mice aged 7-8 weeks were anesthetized by intraperitoneal injection, and 40 μL (each material contained 6 μg LDH) was administered to each mouse by nasal drops. 24 hours after administration, the mice were killed, and 1 mL of pre-cooled PBS was used to wash and collect bronchoalveolar lavage fluid (BALF) through the trachea. After removing the free vaccine and the vaccine that was not taken up by the lung parenchyma and cells, the lungs, mediastinal lymph nodes, and hearts of the mice were removed, and the fluorescence intensity of each organ was analyzed using a small animal in vivo imaging system to analyze the distribution of the vaccine in the body after inhalation.

[0084] As attached Figure 8 As shown, the PDLB nanoformulation showed the highest enrichment effect in both the lungs and proximal mediastinal lymph nodes, and did not produce the side effect of cardiac enrichment. This indicates that after being inhaled, the PDLB nanoformulation can quickly penetrate through the lung mucus layer and act on the lung parenchyma and lung immune cells, and quickly produce lymph node enrichment, which is crucial for the subsequent development of inhaled vaccines based on this nanoformulation.

[0085] Based on the above experimental results, it can be considered that the polydopamine-coated nanoformulation of the present invention and its preparation method and application have uniform and stable size, enhanced mucus penetration ability and high dendritic cell affinity. The inhalation vaccine model product implanted on the basis of this nanoformulation can induce the maturation of dendritic cells and cross-presentation of specific antigens, and maintain efficient enrichment in the lungs and mediastinal lymph nodes after inhalation into the body, and has good application prospects.

[0086] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A method for preparing a nanoformulation based on surface modification of polydopamine, It is characterized in that The steps include: (1) mixing a bovine serum albumin solution and a layered double hydroxide aqueous solution to prepare a solution of bovine serum albumin-coated layered double hydroxide; (2) A solution of bovine serum albumin-coated layered double hydroxide, dopamine and glutaraldehyde were reacted to prepare a nanoformulation based on polydopamine surface modification.

2. The preparation method according to claim 1, It is characterized in that In step (1), the layered double hydroxide is a layered double hydroxide nanoparticle, and its molecular formula is Mg n Al(OH) 2(n+1) Cl (1-x) (CO 3 ) x .mH 2 O, n is selected from 2-4, x is selected from 0-1, and m is an arbitrary number.

3. The preparation method according to claim 1, It is characterized in that In step (1), the mass ratio of bovine serum albumin to layered double hydroxide is 1-8:1; the concentration of the bovine serum albumin solution is 3.5-5.5 mg / mL, and the concentration of the layered double hydroxide aqueous solution is 0.5-1.5 mg / mL; preferably, when the total volume of the bovine serum albumin solution and the layered double hydroxide aqueous solution is ≥100 μL, the mixing is stirring for 25-35 min; when the total volume of the bovine serum albumin solution and the layered double hydroxide aqueous solution is <100 μL, the mixing is stirring and vortexing for 25-35 s.

4. The preparation method according to claim 1, It is characterized in that In step (2), a solution of layered double hydroxide coated with bovine serum albumin is mixed with a dopamine solution, and then reacted with a glutaraldehyde solution to obtain a product; Preferably, the mass ratio of the bovine serum albumin-wrapped layered double hydroxide to dopamine is 2:0.25-2, preferably 2:0.75-1.25; preferably, the concentration of the solution of the bovine serum albumin-wrapped layered double hydroxide is 1.5-2.5 mg / mL, and the concentration of the dopamine solution is 0.25-2 mg / mL; preferably, when the total volume of the solution of the bovine serum albumin-wrapped layered double hydroxide and the dopamine solution is ≥100 μL, the mixing is stirring for 25-35 min; when the total volume of the solution of the bovine serum albumin-wrapped layered double hydroxide and the dopamine solution is <100 μL, the mixing is stirring and vortexing for 25-35 s; Preferably, the volume ratio of the bovine serum albumin-coated layered double hydroxide solution to the glutaraldehyde solution is 1 mL:5-20 μL; the mass concentration of the glutaraldehyde solution is 2%-6%, preferably 4%; preferably, the reaction time is 25-35 min.

5. The polydopamine surface-modified nanoformulation prepared by the method according to any one of claims 1 to 4.

6. An inhaled vaccine, It is characterized in that The nano preparation according to claim 5 is prepared with a nucleic acid immune adjuvant and a protein antigen.

7. The inhalation vaccine according to claim 6, It is characterized in that Nucleic acid immune adjuvants and protein antigens are added into the nano preparation, mixed, and an inhalation vaccine is obtained.

8. The inhalation vaccine according to claim 7, It is characterized in that The protein antigen, bovine serum albumin solution and layered double hydroxide aqueous solution are mixed to prepare bovine serum albumin-coated layered double hydroxide, which is then reacted with dopamine and glutaraldehyde to obtain a nano preparation based on polydopamine surface modification. The obtained nano preparation is mixed with a nucleic acid immune adjuvant to obtain an inhalable vaccine.

9. The inhalation vaccine according to claim 7, It is characterized in that The mass ratio of the nucleic acid immune adjuvant to the layered double hydroxide is 1:20-80, preferably 1:30-60; the mass ratio of the layered double hydroxide to the protein antigen is 1:0.2-1, preferably 1:0.2-0.5; preferably, when the total volume of the nucleic acid immune adjuvant, the protein antigen and the nano preparation is ≥100 μL, the mixing is stirring for 25-35 minutes; when the total volume of the nucleic acid immune adjuvant, the protein antigen and the nano preparation is <100 μL, the mixing is stirring and vortexing for 25-35 seconds.

10. The inhalable vaccine according to any one of claims 6 to 9, It is characterized in that The dosage form of the inhaled vaccine is a nasal administration dosage form; preferably, the inhaled vaccine is a respiratory disease vaccine, preferably a lung disease vaccine.